Search Results
Search for other papers by Taymeyah Al-Toubah in
Google Scholar
PubMed
Università, Vita e Salute, Milan, Italy
Search for other papers by Stefano Partelli in
Google Scholar
PubMed
Search for other papers by Mauro Cives in
Google Scholar
PubMed
Search for other papers by Valentina Andreasi in
Google Scholar
PubMed
Search for other papers by Franco Silvestris in
Google Scholar
PubMed
Università, Vita e Salute, Milan, Italy
Search for other papers by Massimo Falconi in
Google Scholar
PubMed
Search for other papers by Daniel A Anaya in
Google Scholar
PubMed
Search for other papers by Jonathan Strosberg in
Google Scholar
PubMed
-grade tumors are defined as having a mitotic rate of 0–1 per ten high powered fields (HPF) or Ki-67 index of 0–2%, intermediate-grade tumors having a mitotic rate of 2–20 or Ki-67 index of 3–20% and high-grade tumors having a mitotic rate or Ki-67 index >20
Search for other papers by Sisi He in
Google Scholar
PubMed
Search for other papers by Liqian Ma in
Google Scholar
PubMed
Search for other papers by Amy E Baek in
Google Scholar
PubMed
Search for other papers by Anna Vardanyan in
Google Scholar
PubMed
Search for other papers by Varsha Vembar in
Google Scholar
PubMed
Search for other papers by Joy J Chen in
Google Scholar
PubMed
Search for other papers by Adam T Nelson in
Google Scholar
PubMed
Cancer Center at Illinois, University of Illinois at Urbana Champaign, Urbana, Illinois, USA
Search for other papers by Joanna E Burdette in
Google Scholar
PubMed
Cancer Center at Illinois, University of Illinois at Urbana Champaign, Urbana, Illinois, USA
Division of Nutritional Sciences, University of Illinois at Urbana Champaign, Urbana, Illinois, USA
University of Illinois Cancer Center, University of Illinois at Chicago, Chicago, Illinois, USA
Carl R. Woese Institute for Genomic Biology, Anticancer Discovery from Pets to People Theme, University of Illinois at Urbana Champaign, Urbana, Illinois, USA
Search for other papers by Erik R Nelson in
Google Scholar
PubMed
present as high-grade serous carcinomas. Although the ovary itself was considered as the origin of ovarian cancer ( Meyn & Lim 2017 ), recent evidence suggests that the fallopian tube (oviduct) is likely the origin for the majority of high-grade serous
Search for other papers by Annu Makker in
Google Scholar
PubMed
Search for other papers by Madhu Mati Goel in
Google Scholar
PubMed
addition, progesterone inhibited cancer cell migration in Ishikawa cell line due to inhibition of EMT. In high grade EECs showing more widespread myometrial invasion, loss of PR was strongly associated with increased expression of CD44 (a CSC marker) and
Search for other papers by Siker Kimbung in
Google Scholar
PubMed
Search for other papers by Ching-yi Chang in
Google Scholar
PubMed
Search for other papers by Pär-Ola Bendahl in
Google Scholar
PubMed
Search for other papers by Laura Dubois in
Google Scholar
PubMed
Duke Proteomics and Metabolomics Resource, Duke University School of Medicine, Durham, NC, USA
Search for other papers by J Will Thompson in
Google Scholar
PubMed
Search for other papers by Donald P McDonnell in
Google Scholar
PubMed
Clinical Trial Unit, Clinical Studies Sweden, Forum South, Skåne University Hospital, Lund, Sweden
Search for other papers by Signe Borgquist in
Google Scholar
PubMed
seen among high-grade tumors ( Nelson et al. 2013 ). In addition, the concentration of 27HC was found to be higher in ERα-positive breast tumors compared to normal breast tissue, and this was attributed to a corresponding decrease in the expression of
Search for other papers by Carlos Cardenas in
Google Scholar
PubMed
Search for other papers by Ayesha B Alvero in
Google Scholar
PubMed
Search for other papers by Bo Seong Yun in
Google Scholar
PubMed
Search for other papers by Gil Mor in
Google Scholar
PubMed
fallopian tubes are thought to be the cellular origin of either high-grade or low-grade serous ovarian cancer ( Li et al . 2011 , Karst et al . 2011 , Flesken-Nikitin et al . 2013 , Perets et al . 2013 , Ng et al . 2014 ). In addition to possibly
Search for other papers by A Coopes in
Google Scholar
PubMed
Search for other papers by C E Henry in
Google Scholar
PubMed
Search for other papers by E Llamosas in
Google Scholar
PubMed
Search for other papers by C E Ford in
Google Scholar
PubMed
identified aggressive markers in some histologically indolent lesions (type one) or a favourable genomic profile in other tumours assessed as having a poor outlook (type two) ( Levine & The Cancer Genome Atlas Research Network 2013 ). One in four high-grade
Search for other papers by Mathis Grossmann in
Google Scholar
PubMed
Search for other papers by Gary Wittert in
Google Scholar
PubMed
with 11-year follow-up 69 991 men with 5252 incident PCa cases Inverse association of BMI with low-grade PCa (RR, 0.84; 95% CI, 0.66–1.06). Positive association of BMI with high-grade PCa (RR, 1.22; 95% CI, 0.96–1.55) and risk of metastatic or fatal PCa
Search for other papers by Douglas A Gibson in
Google Scholar
PubMed
Search for other papers by Ioannis Simitsidellis in
Google Scholar
PubMed
Search for other papers by Frances Collins in
Google Scholar
PubMed
Search for other papers by Philippa T K Saunders in
Google Scholar
PubMed
the protective effect of tubal ligation is subtype specific with risk reduction for invasive endometrioid and clear cell cancers ( Sieh et al . 2013 b ). Studies on women with BRCA1 / BRCA2 mutations have provided convincing evidence that high-grade
Search for other papers by Wiebke Werner in
Google Scholar
PubMed
Search for other papers by Katharina Detjen in
Google Scholar
PubMed
Search for other papers by Alix Bruneau in
Google Scholar
PubMed
Search for other papers by Isabella Lurje in
Google Scholar
PubMed
Search for other papers by Natalie Nestel in
Google Scholar
PubMed
Search for other papers by Henning Jann in
Google Scholar
PubMed
Search for other papers by Frank Tacke in
Google Scholar
PubMed
Search for other papers by Bertram Wiedenmann in
Google Scholar
PubMed
Clinic for Gastroenterology, Hepatology and Infectious Diseases, University Hospital Düsseldorf, Medical Faculty of Heinrich Heine, University Düsseldorf, Düsseldorf, Germany
Search for other papers by Christoph Roderburg in
Google Scholar
PubMed
Search for other papers by Linda Hammerich in
Google Scholar
PubMed
.3390/cancers12113448 ) Centonze G Lagano V Sabella G Mangogna A Garzone G Filugelli M Belmonte B Cattaneo L Crisafulli V Pellegrinelli A , 2021 Myeloid and T-cell microenvironment immune features identify two prognostic sub-groups in high-grade
Search for other papers by J Hadoux in
Google Scholar
PubMed
Search for other papers by D Malka in
Google Scholar
PubMed
Search for other papers by D Planchard in
Google Scholar
PubMed
Search for other papers by J Y Scoazec in
Google Scholar
PubMed
Search for other papers by C Caramella in
Google Scholar
PubMed
Search for other papers by J Guigay in
Google Scholar
PubMed
Search for other papers by V Boige in
Google Scholar
PubMed
Search for other papers by S Leboulleux in
Google Scholar
PubMed
Search for other papers by P Burtin in
Google Scholar
PubMed
Search for other papers by A Berdelou in
Google Scholar
PubMed
Search for other papers by Y Loriot in
Google Scholar
PubMed
Search for other papers by P Duvillard in
Google Scholar
PubMed
Search for other papers by C N Chougnet in
Google Scholar
PubMed
Search for other papers by D Déandréis in
Google Scholar
PubMed
Search for other papers by M Schlumberger in
Google Scholar
PubMed
Departments of Nuclear Medicine and Endocrine Tumors, Digestive Oncology, Medical Oncology (Thoracic Group), Pathology, Radiology, Centre Antoine Lacassagne, Department of Urologic Oncology, Department of Endocrinology, Department of Biostatistics and Epidemiology, Faculté de Médecine, Gustave Roussy, 114 Rue Edouard Vaillant, F-94800 Villejuif Cedex, France
Search for other papers by I Borget in
Google Scholar
PubMed
Departments of Nuclear Medicine and Endocrine Tumors, Digestive Oncology, Medical Oncology (Thoracic Group), Pathology, Radiology, Centre Antoine Lacassagne, Department of Urologic Oncology, Department of Endocrinology, Department of Biostatistics and Epidemiology, Faculté de Médecine, Gustave Roussy, 114 Rue Edouard Vaillant, F-94800 Villejuif Cedex, France
Search for other papers by M Ducreux in
Google Scholar
PubMed
Search for other papers by E Baudin in
Google Scholar
PubMed
high-grade neuroendocrine tumours? Cancer Chemotherapy and Pharmacology 59 637 – 642 . ( doi:10.1007/s00280-006-0306-6 ). Baudin E 2007 Gastroenteropancreatic endocrine tumors: clinical characterization before therapy . Nature Clinical